Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Ocrelizumab versus Interferon beta 1a in Relapsing Multiple Sclerosis New England Journal of Medicine Hauser, S. L., OPERA Clinical Investigators , et al 2017; 376 (3): 221-234
View details for DOI 10.1056/NEJMoa1601277